Advicenne S.A., a specialty pharmaceutical company, has been making significant strides in the healthcare sector, particularly in the development and commercialization of treatments for rare renal diseases. Headquartered in Paris, France, the company was incorporated in 2007 and has since focused on addressing unmet medical needs through innovative pharmaceutical solutions.
As of January 8, 2026, Advicenne’s stock closed at 1.72 EUR on the NYSE Euronext Paris, reflecting a market capitalization of approximately 25,028,650 EUR. Over the past year, the company’s stock has experienced fluctuations, reaching a 52-week high of 2.1 EUR on January 28, 2025, and a low of 1.104 EUR on July 31, 2025.
Advicenne’s product portfolio includes Sibnayal, a treatment for metabolic disorders, distal renal tubular acidosis, and cystinuria. This product exemplifies the company’s commitment to addressing rare and complex medical conditions. Additionally, Advicenne distributes Likozam, a clobazam formulation designed to alleviate short-term, severe anxiety symptoms. Another key product is Levidcen, a galenic form of levetiracetam, which is used in the treatment of epileptic seizures.
The company’s strategic focus on rare renal diseases and related conditions positions it uniquely within the pharmaceutical industry. By targeting niche markets, Advicenne aims to provide critical therapies to patients with limited treatment options. This approach not only underscores the company’s dedication to improving patient outcomes but also highlights its potential for growth and innovation in the healthcare sector.
Advicenne’s operations extend beyond France, with a presence in international markets, further amplifying its impact in the global healthcare landscape. As the company continues to develop and commercialize its specialized treatments, it remains a key player in the pharmaceutical industry, driven by a mission to enhance the quality of life for patients with rare and challenging medical conditions.
